Skip to main content
TipRanks
Go Ultimate75% OFF

LABORATORIO REIG JOFRE (FEQ1) AI Stock Analysis

1 Followers
DE:FEQ1

LABORATORIO REIG JOFRE

(Frankfurt:FEQ1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Diversified pharmaceutical modelThe combination of proprietary pharmaceutical products and CDMO services gives RJF more than one route to revenue. Its own portfolio can support product-led growth, while outsourced development and manufacturing use existing capabilities to broaden customer and market exposure.
Negative Factors
Sharp 2025 revenue contractionThe 2025 revenue decline represents a material interruption to RJF’s earlier growth trajectory. A contraction of this scale can reduce operating leverage, weaken absorption of fixed costs, and make recovery in earnings dependent on renewed demand or improved pricing.

LABORATORIO REIG JOFRE (FEQ1) vs. iShares MSCI Germany ETF (EWG)

-20%-15%-10%-5%0%5%10%15%20%DE:FEQ1-3.05%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 214.07M
Dividend Yield
0.75%
Average Volume (3M)
―
Price to Earnings (P/E)
30.7
Beta (1Y)
0.34
Revenue Growth
-0.42%
EPS Growth
4.56%
Country
Germany
Employees
1,512
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

LABORATORIO REIG JOFRE Business Overview & Revenue Model

Company Description

Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs,...

LABORATORIO REIG JOFRE Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:FEQ1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ES:ROVIES:ROVI76OutperformEUR 3.52B17.3129.17%1.38%14.41%69.69%
ES:GRFES:GRF75OutperformEUR 6.93B16.128.83%0.71%1.03%30.59%
ES:ALMES:ALM70OutperformEUR 2.32B31.694.81%1.73%9.67%174.00%
ES:FAEES:FAE69NeutralEUR 1.58B11.6818.19%2.52%31.88%-20.09%
ES:CBAVES:CBAV66NeutralEUR 890.17M19.5741.91%2.87%10.89%17.12%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

-20%0%20%40%DE:FEQ1ES:ALMES:CBAVES:FAEES:GRFES:ROVIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:FEQ1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:FEQ1LABORATORIO REIG JOFRE2.54-0.08-3.05%
ES:ALMAlmirall SA10.50-1.78-14.47%
ES:CBAVClinica Baviera55.8016.0640.43%
ES:FAEFaes Farma5.010.5011.21%
ES:GRFGrifols (0RDU)11.531.3713.50%
ES:ROVILaboratorios Farmaceuticos Rovi68.5010.8118.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.